Australia markets closed

Emyria Limited (EMD.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0460-0.0040 (-8.00%)
At close: 04:10PM AEST

Emyria Limited

D2, 661 Newcastle Street
Leederville, WA 6007
61 8 6559 2800

IndustryHealth Information Services
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Michael WinloMD & Director421.04kN/AN/A
Dr. Alistair VickeryExecutive Medical Director & Director381.42kN/AN/A
Mr. Joseph Daniel Ohayon ACA, MBA Intl Bus.Chief Financial OfficerN/AN/AN/A
Ms. Sara PolanskiCommunications & Brand ManagerN/AN/AN/A
Ms. Tracie ErnenweinHead of Research & Drug DevelopmentN/AN/AN/A
Mary-Ann RennieHead of Corporate OperationsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.

Corporate governance

Emyria Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.